Want to see ALURD full AI Analyst Report?
Top Page
Allurion Technologies
(OTC:ALURD)
Select Model
Select Model
Rating:41Neutral
Price Target:
$5.50
▲(587.50% Upside)
Action:Reiterated
Date:07/03/26
The score is pressured primarily by weak financial performance (shrinking revenue, very large losses, heavy cash burn, and negative equity indicating elevated funding risk) and bearish technicals (price below all major moving averages with negative MACD). Valuation provides limited offset because the negative P/E reflects ongoing losses and no dividend yield is available.
Positive Factors
High gross margin (~53%)
A ~53% gross margin provides durable profit per unit, supporting path to break-even if scale or fixed-cost structure improves. High gross margins give pricing flexibility and the potential to fund marketing and clinical support without full reliance on external capital.
Negative Factors
Steep multi-year revenue decline
Sustained revenue contraction erodes economies of scale, weakens market foothold, and makes fixed costs and sales investments harder to support. Long-term recovery will require reaccelerating adoption or new channels; without that, profitability prospects remain constrained.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margin (~53%)
A ~53% gross margin provides durable profit per unit, supporting path to break-even if scale or fixed-cost structure improves. High gross margins give pricing flexibility and the potential to fund marketing and clinical support without full reliance on external capital.
Read all positive factors
Allurion Technologies (ALURD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.50M
Dividend YieldN/A
Average Volume (3M)88.72K
Price to Earnings (P/E)―
Beta (1Y)2.81
Revenue Growth-55.49%
EPS Growth21.55%
CountryUS
Employees134
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-56.40
Shares Outstanding1,000,417
10 Day Avg. Volume45,410
30 Day Avg. Volume88,723
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-0.12
Price to Sales (P/S)0.61
P/FCF Ratio-0.32
Enterprise Value/Market Cap5.29
Enterprise Value/Revenue2.31
Enterprise Value/Gross Profit4.39
Enterprise Value/Ebitda-0.75
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-20.25
Revenue Forecast (FY)$13.70M
Allurion Technologies Business Overview & Revenue Model
Company Description
Allurion Technologies Inc. is dedicated to combating obesity by offering a comprehensive weight management ecosystem designed for individuals with excess weight. At the core of its solution is the Allurion Program, featuring the innovative Allurio...
How the Company Makes Money
Allurion primarily generates revenue from the commercialization of its weight-loss solution centered on the Allurion Balloon. Revenue is earned through the sale of the balloon and associated program components delivered to healthcare providers/cli...
Allurion Technologies Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
14
Very Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Allurion Technologies Technical Analysis
Negative
0.80
Price Trends
10.13
Negative
11.27
Negative
18.28
Negative
Market Momentum
-1.88
Positive
40.00
Neutral
38.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALURD, the sentiment is Negative. The current price of 0.8 is below the 20-day moving average (MA) of 7.98, below the 50-day MA of 10.13, and below the 200-day MA of 18.28, indicating a bearish trend. The MACD of -1.88 indicates Positive momentum. The RSI at 40.00 is Neutral, neither overbought nor oversold. The STOCH value of 38.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALURD.
Allurion Technologies Risk Analysis
Allurion Technologies disclosed 88 risk factors in its most recent earnings report. Allurion Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Allurion Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $6.74M | -0.11 | -279.58% | ― | 107.26% | 71.98% | |
46 Neutral | $11.02M | -0.09 | -164.92% | ― | -9.46% | 18.03% | |
46 Neutral | $7.42M | >-0.01 | -57.19% | ― | ― | 27.91% | |
45 Neutral | $19.67M | -5.95 | -148.64% | ― | 7.73% | 55.39% | |
41 Neutral | $5.50M | -0.13 | 58.76% | ― | -55.49% | 21.55% | |
41 Neutral | $12.08M | -0.34 | -204.04% | ― | -59.95% | 56.67% |
* Healthcare Sector Average
ALURD
Allurion Technologies
5.50
-32.15
-85.39%
IRIX
Iridex
1.13
0.18
18.95%
SINT
Sintx Technologies
1.90
-1.36
-41.72%
CODX
Co-Diagnostics
2.99
-5.32
-64.02%
XAIR
Beyond Air
0.47
-3.11
-86.93%
NVNO
enVVeno Medical
11.11
-128.54
-92.04%
Allurion Technologies Corporate Events
Executive/Board Changes
Allurion Technologies Board Member Resigns, Audit Chair Vacant
Neutral
Jun 30, 2026
Allurion Technologies, Inc. reported that on June 24, 2026, board member R. Jason Richey resigned from the company’s board of directors and stepped down as chairperson of its Audit Committee, effective the same day. The company stated that h...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.